TW201836604A - Ep4拮抗劑用於治療發炎疼痛之用途 - Google Patents

Ep4拮抗劑用於治療發炎疼痛之用途 Download PDF

Info

Publication number: TW201836604A
Authority: TW; Taiwan
Prior art keywords: compound; pain; receptor; inhibitors; treatment
Prior art date: 2017-03-10

Application number

TW107107888A

Other languages

English (en)

Chinese (zh)

Inventor

傑恩奈吉爾

史帝芬包爾

梅克歐班朵福

馬可斯寇許

吉諾特蘭格爾

安妮-瑪利高帝諾-索何

Original Assignee

德商拜耳製藥公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-03-10

Filing date

2018-03-08

Publication date

2018-10-16

2018-03-08 Application filed by 德商拜耳製藥公司 filed Critical 德商拜耳製藥公司

2018-10-16 Publication of TW201836604A publication Critical patent/TW201836604A/zh

Links

206010065390 Inflammatory pain Diseases 0.000 title claims abstract description 25
238000011282 treatment Methods 0.000 title claims abstract description 19
239000005557 antagonist Substances 0.000 title claims description 14
229940125904 compound 1 Drugs 0.000 claims abstract description 64
208000002193 Pain Diseases 0.000 claims description 29
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 28
230000036407 pain Effects 0.000 claims description 27
229960002986 dinoprostone Drugs 0.000 claims description 20
XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 20
101150109738 Ptger4 gene Proteins 0.000 claims description 19
239000003112 inhibitor Substances 0.000 claims description 17
230000004913 activation Effects 0.000 claims description 13
150000001875 compounds Chemical class 0.000 claims description 13
201000009273 Endometriosis Diseases 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 10
230000001575 pathological effect Effects 0.000 claims description 9
239000000556 agonist Substances 0.000 claims description 6
201000008482 osteoarthritis Diseases 0.000 claims description 6
102000005962 receptors Human genes 0.000 claims description 6
108020003175 receptors Proteins 0.000 claims description 6
206010058031 Joint adhesion Diseases 0.000 claims description 5
201000002661 Spondylitis Diseases 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 5
108091007960 PI3Ks Proteins 0.000 claims description 4
208000004550 Postoperative Pain Diseases 0.000 claims description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 4
229940111134 coxibs Drugs 0.000 claims description 4
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
102000015694 estrogen receptors Human genes 0.000 claims description 4
108010038795 estrogen receptors Proteins 0.000 claims description 4
238000000034 method Methods 0.000 claims description 4
239000000849 selective androgen receptor modulator Substances 0.000 claims description 4
229940095743 selective estrogen receptor modulator Drugs 0.000 claims description 4
239000000333 selective estrogen receptor modulator Substances 0.000 claims description 4
231100000075 skin burn Toxicity 0.000 claims description 4
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 3
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims description 3
239000012190 activator Substances 0.000 claims description 3
230000003042 antagnostic effect Effects 0.000 claims description 3
229940043355 kinase inhibitor Drugs 0.000 claims description 3
231100000252 nontoxic Toxicity 0.000 claims description 3
230000003000 nontoxic effect Effects 0.000 claims description 3
239000003757 phosphotransferase inhibitor Substances 0.000 claims description 3
239000002379 progesterone receptor modulator Substances 0.000 claims description 3
102000004169 proteins and genes Human genes 0.000 claims description 3
108090000623 proteins and genes Proteins 0.000 claims description 3
102100037426 17-beta-hydroxysteroid dehydrogenase type 1 Human genes 0.000 claims description 2
239000002677 5-alpha reductase inhibitor Substances 0.000 claims description 2
101100322915 Caenorhabditis elegans akt-1 gene Proteins 0.000 claims description 2
102100032857 Cyclin-dependent kinase 1 Human genes 0.000 claims description 2
101710106279 Cyclin-dependent kinase 1 Proteins 0.000 claims description 2
102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 2
108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 2
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims description 2
101000919849 Homo sapiens Cytochrome c oxidase subunit 1 Proteins 0.000 claims description 2
101000605122 Homo sapiens Prostaglandin G/H synthase 1 Proteins 0.000 claims description 2
206010021143 Hypoxia Diseases 0.000 claims description 2
108091054455 MAP kinase family Proteins 0.000 claims description 2
102000043136 MAP kinase family Human genes 0.000 claims description 2
101150018665 MAPK3 gene Proteins 0.000 claims description 2
101150100676 Map2k1 gene Proteins 0.000 claims description 2
108010074633 Mixed Function Oxygenases Proteins 0.000 claims description 2
102000008109 Mixed Function Oxygenases Human genes 0.000 claims description 2
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 claims description 2
108091008611 Protein Kinase B Proteins 0.000 claims description 2
102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 claims description 2
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 2
239000002671 adjuvant Substances 0.000 claims description 2
239000003098 androgen Substances 0.000 claims description 2
239000003886 aromatase inhibitor Substances 0.000 claims description 2
SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 claims description 2
239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims description 2
230000006698 induction Effects 0.000 claims description 2
239000003226 mitogen Substances 0.000 claims description 2
239000002742 neurokinin 1 receptor antagonist Substances 0.000 claims description 2
229940127234 oral contraceptive Drugs 0.000 claims description 2
239000003539 oral contraceptive agent Substances 0.000 claims description 2
229960005489 paracetamol Drugs 0.000 claims description 2
239000000186 progesterone Substances 0.000 claims description 2
229960003387 progesterone Drugs 0.000 claims description 2
230000019491 signal transduction Effects 0.000 claims description 2
230000000699 topical effect Effects 0.000 claims description 2
101000579300 Homo sapiens Prostaglandin F2-alpha receptor Proteins 0.000 claims 2
102000038030 PI3Ks Human genes 0.000 claims 2
102100028248 Prostaglandin F2-alpha receptor Human genes 0.000 claims 2
OJYIBEYSBXIQOP-UHFFFAOYSA-N 1-methoxy-4-[2-(4-methoxyphenyl)propan-2-yl]benzene Chemical compound C1=CC(OC)=CC=C1C(C)(C)C1=CC=C(OC)C=C1 OJYIBEYSBXIQOP-UHFFFAOYSA-N 0.000 claims 1
101710147298 17-beta-hydroxysteroid dehydrogenase type 1 Proteins 0.000 claims 1
102000003858 Chymases Human genes 0.000 claims 1
108090000227 Chymases Proteins 0.000 claims 1
101710174215 Estradiol 17-beta-dehydrogenase 1 Proteins 0.000 claims 1
229940123821 Neurokinin 1 receptor antagonist Drugs 0.000 claims 1
108010087999 Steryl-Sulfatase Proteins 0.000 claims 1
102100038021 Steryl-sulfatase Human genes 0.000 claims 1
102000005262 Sulfatase Human genes 0.000 claims 1
229940046844 aromatase inhibitors Drugs 0.000 claims 1
229940088597 hormone Drugs 0.000 claims 1
239000005556 hormone Substances 0.000 claims 1
230000007954 hypoxia Effects 0.000 claims 1
PFPSZGPAQFBVHZ-UHFFFAOYSA-N n-(3-chlorophenyl)-2-[(4-phenyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)sulfanyl]acetamide Chemical compound ClC1=CC=CC(NC(=O)CSC=2N(C(C=3C=CN=CC=3)=NN=2)C=2C=CC=CC=2)=C1 PFPSZGPAQFBVHZ-UHFFFAOYSA-N 0.000 claims 1
239000000825 pharmaceutical preparation Substances 0.000 claims 1
239000000583 progesterone congener Substances 0.000 claims 1
108060007951 sulfatase Proteins 0.000 claims 1
210000004027 cell Anatomy 0.000 description 31
230000000694 effects Effects 0.000 description 24
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
241001465754 Metazoa Species 0.000 description 12
238000012360 testing method Methods 0.000 description 12
239000003981 vehicle Substances 0.000 description 11
241000700159 Rattus Species 0.000 description 8
206010030113 Oedema Diseases 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
238000002866 fluorescence resonance energy transfer Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
-1 aryl decylamine Chemical compound 0.000 description 6
238000003556 assay Methods 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
239000000700 radioactive tracer Substances 0.000 description 6
239000013543 active substance Substances 0.000 description 5
239000000203 mixture Substances 0.000 description 5
230000035755 proliferation Effects 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
QAOBBBBDJSWHMU-WMBBNPMCSA-N 16,16-dimethylprostaglandin E2 Chemical compound CCCCC(C)(C)[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O QAOBBBBDJSWHMU-WMBBNPMCSA-N 0.000 description 4
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
238000000540 analysis of variance Methods 0.000 description 4
230000010339 dilation Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
210000002683 foot Anatomy 0.000 description 4
229940125425 inverse agonist Drugs 0.000 description 4
238000011866 long-term treatment Methods 0.000 description 4
239000012139 lysis buffer Substances 0.000 description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
238000007911 parenteral administration Methods 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
208000004454 Hyperalgesia Diseases 0.000 description 3
208000035154 Hyperesthesia Diseases 0.000 description 3
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
230000002860 competitive effect Effects 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
238000001514 detection method Methods 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
229960001680 ibuprofen Drugs 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
238000005259 measurement Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
210000000929 nociceptor Anatomy 0.000 description 3
230000003389 potentiating effect Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
230000000770 proinflammatory effect Effects 0.000 description 3
229940044551 receptor antagonist Drugs 0.000 description 3
239000002464 receptor antagonist Substances 0.000 description 3
230000004044 response Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
238000005160 1H NMR spectroscopy Methods 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
206010006811 Bursitis Diseases 0.000 description 2
208000004483 Dyspareunia Diseases 0.000 description 2
201000005569 Gout Diseases 0.000 description 2
102000003964 Histone deacetylase Human genes 0.000 description 2
108090000353 Histone deacetylase Proteins 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
101710122864 Major tegument protein Proteins 0.000 description 2
101710148592 PTS system fructose-like EIIA component Proteins 0.000 description 2
101710169713 PTS system fructose-specific EIIA component Proteins 0.000 description 2
208000000450 Pelvic Pain Diseases 0.000 description 2
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
208000025747 Rheumatic disease Diseases 0.000 description 2
101710199973 Tail tube protein Proteins 0.000 description 2
208000004760 Tenosynovitis Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000001270 agonistic effect Effects 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
230000006399 behavior Effects 0.000 description 2
238000011088 calibration curve Methods 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
230000006037 cell lysis Effects 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
238000012054 celltiter-glo Methods 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000012173 estrus Effects 0.000 description 2
230000005284 excitation Effects 0.000 description 2
238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229960005181 morphine Drugs 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
239000002674 ointment Substances 0.000 description 2
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
210000000578 peripheral nerve Anatomy 0.000 description 2
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
238000011533 pre-incubation Methods 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000829 suppository Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 2
230000009278 visceral effect Effects 0.000 description 2
238000005303 weighing Methods 0.000 description 2
DIIIISSCIXVANO-UHFFFAOYSA-N 1,2-Dimethylhydrazine Chemical compound CNNC DIIIISSCIXVANO-UHFFFAOYSA-N 0.000 description 1
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
NKWCGTOZTHZDHB-UHFFFAOYSA-N 1h-imidazol-1-ium-4-carboxylate Chemical compound OC(=O)C1=CNC=N1 NKWCGTOZTHZDHB-UHFFFAOYSA-N 0.000 description 1
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 description 1
COYPLDIXZODDDL-UHFFFAOYSA-N 3h-benzimidazole-5-carboxylic acid Chemical class OC(=O)C1=CC=C2N=CNC2=C1 COYPLDIXZODDDL-UHFFFAOYSA-N 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
229940122815 Aromatase inhibitor Drugs 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
208000000094 Chronic Pain Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
208000007342 Diabetic Nephropathies Diseases 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
229910052693 Europium Inorganic materials 0.000 description 1
101710089384 Extracellular protease Proteins 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
101001117509 Homo sapiens Prostaglandin E2 receptor EP4 subtype Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
102100035792 Kininogen-1 Human genes 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
241000282567 Macaca fascicularis Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
150000001200 N-acyl ethanolamides Chemical class 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000007072 Nerve Growth Factors Human genes 0.000 description 1
208000001294 Nociceptive Pain Diseases 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
102100024450 Prostaglandin E2 receptor EP4 subtype Human genes 0.000 description 1
102000000471 Prostaglandin F receptors Human genes 0.000 description 1
108050008995 Prostaglandin F receptors Proteins 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
210000003815 abdominal wall Anatomy 0.000 description 1
230000009471 action Effects 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
230000008484 agonism Effects 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000000708 anti-progestin effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000003418 antiprogestin Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
210000000544 articulatio talocruralis Anatomy 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
230000003491 cAMP production Effects 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
210000000078 claw Anatomy 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000003405 delayed action preparation Substances 0.000 description 1
208000033679 diabetic kidney disease Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
210000004921 distal colon Anatomy 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000010410 dusting Methods 0.000 description 1
230000000317 effect on hyperalgesia Effects 0.000 description 1
150000002066 eicosanoids Chemical class 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000002621 endocannabinoid Substances 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
150000002240 furans Chemical class 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
239000008187 granular material Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000001023 inorganic pigment Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000004068 intracellular signaling Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
210000003975 mesenteric artery Anatomy 0.000 description 1
CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
229940095102 methyl benzoate Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
210000004126 nerve fiber Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
230000008052 pain pathway Effects 0.000 description 1
239000006072 paste Substances 0.000 description 1
JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
235000014347 soups Nutrition 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000005845 steroid sulfates Chemical class 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000001300 stimulation of adenylate cyclase Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000012549 training Methods 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
239000006213 vaginal ring Substances 0.000 description 1
229940044953 vaginal ring Drugs 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Anesthesiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TW107107888A 2017-03-10 2018-03-08 Ep4拮抗劑用於治療發炎疼痛之用途 TW201836604A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP17160290		2017-03-10
??17160290.7		2017-03-10

Publications (1)

Publication Number	Publication Date
TW201836604A true TW201836604A (zh)	2018-10-16

Family

ID=58266489

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW107107888A TW201836604A (zh)	2017-03-10	2018-03-08	Ep4拮抗劑用於治療發炎疼痛之用途

Country Status (2)

Country	Link
TW (1)	TW201836604A (fr)
WO (1)	WO2018162562A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2019038156A1 (fr) *	2017-08-22	2019-02-28	Bayer Pharma Aktiengesellschaft	Utilisation d'un antagoniste d'ep4 pour le traitement de l'arthrite

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HN2001000224A (es)	2000-10-19	2002-06-13	Pfizer	Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
MXPA04009243A (es)	2002-04-12	2005-06-08	Pfizer	Uso de ligandos para el receptor ep4 en el tratamiento de enfermedades vinculadas a il-6.
PT1603893E (pt)	2003-01-29	2008-08-21	Asterand Uk Ltd	Antagonistas dos receptores ep4
RU2006137076A (ru)	2004-04-20	2008-04-27	Пфайзер Продактс Инк. (Us)	Комбинации, содержащие лиганды рецептора альфа-2-дельта
EP1756043B1 (fr)	2004-05-04	2009-07-01	RaQualia Pharma Inc	Composes aryl- ou heteroarylamides ortho-substitues
US20050268605A1 (en)	2004-06-02	2005-12-08	Wood James G	Method and apparatus for forming a heat exchanger
WO2007121578A1 (fr)	2006-04-24	2007-11-01	Merck Frosst Canada Ltd.	Dérivés d'indolamide comme antagonistes du récepteur ep4
ES2421453T3 (es)	2006-08-11	2013-09-02	Merck Frosst Canada Ltd	Derivados de tiofenocarboxamida como ligandos del receptor EP4
AU2008221194B2 (en)	2007-02-26	2013-06-27	Merck Canada Inc.	Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists
EP2460787A1 (fr)	2007-07-03	2012-06-06	Astellas Pharma Inc.	Composés d'amide et leur utilidsation comme anagonistes de la PGE2.
US20100204487A1 (en)	2007-08-09	2010-08-12	Ian Davies	Process for making thiophene carboxamide derivatives
UA115576C2 (uk)	2012-12-06	2017-11-27	Байєр Фарма Акцієнгезелльшафт	Похідні бензимідазолу як антагоністи ер4
TW201607943A (zh) *	2013-12-19	2016-03-01	拜耳製藥公司	作為ｅｐ４配體之新穎苯并咪唑衍生物

2018
- 2018-03-07 WO PCT/EP2018/055615 patent/WO2018162562A1/fr not_active Ceased
- 2018-03-08 TW TW107107888A patent/TW201836604A/zh unknown

Also Published As

Publication number	Publication date
WO2018162562A1 (fr)	2018-09-13

Publication	Publication Date	Title
US10730856B2 (en)	2020-08-04	Benzimidazole derivatives as EP4 ligands
TW200418483A (en)	2004-10-01	Methods of treating cancer and related methods
KR20170003527A (ko)	2017-01-09	경구 투여용 펜토산 폴리설페이트 염의 조성물
PT1149579E (pt)	2007-02-28	Utilização de um agonista/antagonista de estrogénio para tratamento da disfunção sexual feminina
KR102839190B1 (ko)	2025-07-28	자궁내막증의 치료를 위한 고나도트로핀 방출호르몬 길항제 투약요법
CN101861151A (zh)	2010-10-13	使用组蛋白脱乙酰基酶hdac1、hdac2和/或hdac3的选择性抑制剂和微管稳定剂的癌症组合治疗
JP2013518909A (ja)	2013-05-23	アロステリックキナーゼ阻害が関係する治療方法および組成物
KR20140033442A (ko)	2014-03-18	제 2형 당뇨병 관련 통증에서 시그마 리간드의 이용
EP3166610A1 (fr)	2017-05-17	Procédés de traitement de troubles neurologiques
KR20220045198A (ko)	2022-04-12	에스트로겐-의존성 장애의 치료를 위한 gnrh 길항제
US20190322633A1 (en)	2019-10-24	Stromal derived factor inhibition and cxcr4 blockade
JP2007530664A (ja)	2007-11-01	ゲートイオンチャンネルを調節するための組成物及び方法
TW201836604A (zh)	2018-10-16	Ep4拮抗劑用於治療發炎疼痛之用途
US20100216778A1 (en)	2010-08-26	Pain remedy containing rock inhibitor
KR20120099215A (ko)	2012-09-07	다운 증후군을 치료하기 위한 방법 및 약학적 조성물
Sanna et al.	2011	Dopamine D2-like receptor agonists induce penile erection in male rats: differential role of D2, D3 and D4 receptors in the paraventricular nucleus of the hypothalamus
CN101730467A (zh)	2010-06-09	神经病性疼痛的治疗
US8101580B2 (en)	2012-01-24	Therapeutic agent for irritable bowel syndrome
EP4243829A1 (fr)	2023-09-20	Méthodes d'administration du rélugolix
CN106243096B (zh)	2019-11-29	三环类药物的新用途
US20110251219A1 (en)	2011-10-13	Treatment for glomerulonephritis with 2-[4-(7-ethyl-5h-pyrrolo[2,3-b]pyrazin-6-yl)phenyl]propan-2-ol
US20190307758A1 (en)	2019-10-10	Trpa1 antagonists for use in the treatment of atopic dermatitis
JPH1135483A (ja)	1999-02-09	頻尿又は尿失禁の治療剤又は予防剤
US20230285347A1 (en)	2023-09-14	Preterm Labour with Prostaglandin E2 Receptor Agonists
JP2024515727A (ja)	2024-04-10	チューブリン重合阻害剤としての代謝的に安定なピリミジニルジヒドロキノキサリノン